Aodong Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aodong Qiu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Xinghua Lu
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206, USA
2 shared publications Binfeng Lu
Center for Discovery and Innovation, Hackensack Meridian Health , 111 Ideation Way, Nutley, NJ, 07110
1 shared publicationBoyang Sun
Mohamed bin Zayed University of Artificial Intelligence , Building 1B, Masdar City, Abu Dhabi
1 shared publicationBryan Andrews
Department of Psychiatry & Behavioral Sciences, University of Minnesota , 2312 S 6th St, Minneapolis, MN, 55454
1 shared publicationChi-Ping Day
Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, United States
1 shared publication- Chih-Hsuan Wei
National Institutes of Health, Bethesda, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (Supplement)
Knowledge-guided contextual gene set analysis with large language models.
Gene set analysis (GSA) is a foundational approach for interpreting genomic data of diseases by linking genes to biological processes. However, conventional GSA methods overlook clinical context of the analyses, often generating long lists of enriched pathways with redundant, nonspecific, or irrelevant results. Interpreting these requires extensive, ad-hoc manual effort, reducing both reliability and reproducibility. We introduce cGSA, a novel AI-driven framework that enhances GSA by incorporating context-aware pathway prioritization. cGSA integrates gene cluster detection, enrichment analysis, and large language models to identify pathways that are not only statistically significant but also biologically meaningful. Benchmarking on 102 curated gene sets across 19 diseases and ten disease-related biological mechanisms shows that cGSA outperforms baseline methods by over 30%, with expert validation confirming its increased precision and interpretability. Two independent case studies in melanoma and breast cancer further demonstrate its potential to uncover context-specific insights and support targeted hypothesis. The demo website is publicly available at https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/cGSA/, while the data and code can be accessed at https://github.com/ncbi-nlp/cGSA.
- 1 July 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (Supplement)
Open AccessKnowledge-guided contextual gene set analysis with large language models.
Gene set analysis (GSA) is a foundational approach for interpreting genomic data of diseases by linking genes to biological processes. However, conventional GSA methods overlook clinical context of the analyses, often generating long lists of enriched pathways with redundant, nonspecific, or irrelevant results. Interpreting these requires extensive, ad-hoc manual effort, reducing both reliability and reproducibility. We introduce cGSA, a novel AI-driven framework that enhances GSA by incorporating context-aware pathway prioritization. cGSA integrates gene cluster detection, enrichment analysis, and large language models to identify pathways that are not only statistically significant but also biologically meaningful. Benchmarking on 102 curated gene sets across 19 diseases and ten disease-related biological mechanisms shows that cGSA outperforms baseline methods by over 30%, with expert validation confirming its increased precision and interpretability. Two independent case studies in melanoma and breast cancer further demonstrate its potential to uncover context-specific insights and support targeted hypothesis. The demo website is publicly available at https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/cGSA/, while the data and code can be accessed at https://github.com/ncbi-nlp/cGSA.
- Open Access
- 1 March 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (2)
Causal modeling reveals cell–cell communication dynamics in the tumor microenvironment during anti-PD-1 therapy in breast cancer patients
Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 axis has transformed breast cancer treatment, yet how therapy reshapes the tumor microenvironment (TME) through cell–cell communication (CCC) remains unclear. Existing CCC inference methods relying on correlations have difficulty distinguishing genuine signaling from confounded associations. Here, we present a causal inference framework that uses single-cell data and leverages treatment as an instrumental variable to identify genuine CCC networks, referred to as scIVCCC, which infers causal signal transduction across cell types. Applying scIVCCC to single-cell RNA-seq data from 31 breast cancer patients before and after anti-PD-1 therapy, we constructed causal CCC networks linking exhausted T cells to tumor-associated macrophages (TAMs). Our analysis reveals a dual role of T cell-macrophage crosstalk: CD4+ and CD8+ exhausted T cells drive anti-tumor M1-like TAMs activation via TNF–TNFRSF1A, TNFSF14–LTBR, and ICAM1–ITGAL/ITGB2. Conversely, they also induce immunosuppressive M2-like polarization through pathways such as TNF–TNFRSF1B (TNFR2), TNFSF14–TNFRSF14 (HVEM), and RPS19–C5AR1, which likely contribute to therapeutic resistance. Our causal modeling suggests that receptors within these networks, such as C5AR1, TNFR2, and CSF1R, may serve as potential candidates for combination therapies to enhance anti-PD-1 efficacy. Collectively, these findings demonstrate that scIVCCC offers a robust framework for dissecting treatment-induced CCC dynamics and prioritizing actionable targets for clinical translation.
- 1 March 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (2)
Open AccessCausal modeling reveals cell–cell communication dynamics in the tumor microenvironment during anti-PD-1 therapy in breast cancer patients
Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 axis has transformed breast cancer treatment, yet how therapy reshapes the tumor microenvironment (TME) through cell–cell communication (CCC) remains unclear. Existing CCC inference methods relying on correlations have difficulty distinguishing genuine signaling from confounded associations. Here, we present a causal inference framework that uses single-cell data and leverages treatment as an instrumental variable to identify genuine CCC networks, referred to as scIVCCC, which infers causal signal transduction across cell types. Applying scIVCCC to single-cell RNA-seq data from 31 breast cancer patients before and after anti-PD-1 therapy, we constructed causal CCC networks linking exhausted T cells to tumor-associated macrophages (TAMs). Our analysis reveals a dual role of T cell-macrophage crosstalk: CD4+ and CD8+ exhausted T cells drive anti-tumor M1-like TAMs activation via TNF–TNFRSF1A, TNFSF14–LTBR, and ICAM1–ITGAL/ITGB2. Conversely, they also induce immunosuppressive M2-like polarization through pathways such as TNF–TNFRSF1B (TNFR2), TNFSF14–TNFRSF14 (HVEM), and RPS19–C5AR1, which likely contribute to therapeutic resistance. Our causal modeling suggests that receptors within these networks, such as C5AR1, TNFR2, and CSF1R, may serve as potential candidates for combination therapies to enhance anti-PD-1 efficacy. Collectively, these findings demonstrate that scIVCCC offers a robust framework for dissecting treatment-induced CCC dynamics and prioritizing actionable targets for clinical translation.